Could a common diabetes drug fix a rare heart condition?
NCT ID NCT07146880
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small study will test whether empagliflozin, a drug typically used for diabetes, can improve abnormal heart patterns in people with Brugada syndrome. Ten participants will take the drug daily for three months, and researchers will monitor their heart rhythms and any side effects. The goal is to see if the drug can reduce the risk of dangerous heart events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin (a diabetes drug that lowers blood sugar by helping the kidneys remove it)
- What this could lead to
- If it works, this could point toward a new treatment option for Brugada syndrome, a rare heart condition that can cause dangerous heart rhythms.
- What could go wrong
- This is a very small early-phase trial with only 10 people, so results may not apply to everyone. The drug also has known side effects like infections and kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRUGADA SYNDROME (BRS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, Taiwan, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.